Sierra Summit Advisors LLC Acquires New Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Sierra Summit Advisors LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 20,003 shares of the company's stock, valued at approximately $484,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rockefeller Capital Management L.P. lifted its holdings in Hims & Hers Health by 5.8% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company's stock valued at $622,000 after purchasing an additional 1,864 shares in the last quarter. HighTower Advisors LLC acquired a new position in shares of Hims & Hers Health in the third quarter valued at approximately $207,000. State Street Corp lifted its stake in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after buying an additional 206,078 shares during the period. Wellington Management Group LLP lifted its stake in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after buying an additional 883,230 shares during the period. Finally, MML Investors Services LLC acquired a new stake in Hims & Hers Health during the third quarter worth approximately $197,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Morgan Stanley downgraded Hims & Hers Health from an "overweight" rating to an "equal weight" rating and increased their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Bank of America lifted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a report on Tuesday, March 18th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Finally, Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $38.25.

Remove Ads

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $0.32 during midday trading on Friday, hitting $27.13. 16,210,541 shares of the company's stock traded hands, compared to its average volume of 15,146,132. The firm's fifty day moving average price is $38.75 and its two-hundred day moving average price is $30.46. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The company has a market cap of $6.03 billion, a PE ratio of 61.66 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 17,304 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $31.00, for a total transaction of $536,424.00. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at approximately $6,001,631. This represents a 8.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 54,153 shares of Hims & Hers Health stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the completion of the sale, the insider now owns 165,650 shares of the company's stock, valued at approximately $4,952,935. This trade represents a 24.64 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 835,884 shares of company stock valued at $31,659,701. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.